Novo Nordisk A/S (NYSE:NVO) has been assigned an average recommendation of “Hold” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company.
NVO has been the topic of a number of analyst reports. BidaskClub upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Bank of America raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, September 6th. Zacks Investment Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research report on Wednesday, September 13th. BNP Paribas downgraded shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Monday, September 25th. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Friday.
Shares of Novo Nordisk A/S (NYSE NVO) opened at $51.99 on Monday. The stock has a market cap of $132,574.50, a P/E ratio of 22.70, a PEG ratio of 3.10 and a beta of 0.63. Novo Nordisk A/S has a 12 month low of $32.83 and a 12 month high of $52.32.
Hedge funds have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 6.1% in the second quarter. Proficio Capital Partners LLC now owns 2,622 shares of the company’s stock worth $111,000 after purchasing an additional 150 shares during the period. AlphaMark Advisors LLC boosted its holdings in Novo Nordisk A/S by 1.1% in the second quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after purchasing an additional 30 shares during the period. MUFG Americas Holdings Corp boosted its holdings in Novo Nordisk A/S by 100.0% in the second quarter. MUFG Americas Holdings Corp now owns 3,000 shares of the company’s stock worth $129,000 after purchasing an additional 1,500 shares during the period. Zions Bancorporation boosted its holdings in Novo Nordisk A/S by 677.1% in the third quarter. Zions Bancorporation now owns 2,852 shares of the company’s stock worth $137,000 after purchasing an additional 2,485 shares during the period. Finally, Parallel Advisors LLC boosted its holdings in Novo Nordisk A/S by 44.4% in the second quarter. Parallel Advisors LLC now owns 4,108 shares of the company’s stock worth $174,000 after purchasing an additional 1,264 shares during the period. 6.18% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/04/novo-nordisk-as-nvo-receives-consensus-recommendation-of-hold-from-brokerages.html.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.